Email Alerts

Looking for a tax loss?

Yesterday Movano filed an S1 indicating they intend to raise $41 million. Just in case you have never heard of the company this is how they describe themselves in the S1. “We are a health-focused technology company developing simple, smart and personalized devices designed to help individuals on their health journey maintain good health today and prevent and manage chronic diseases in the future. We are developing a proprietary platform that uses...

Playing a different game

This Sunday the Kansas City Chiefs and the Tampa Bay Buccaneers will face off in Tampa to decide who rules the NFL world. In our wacky world Apple, Amazon and Google are facing off to decide which of these tech behemoths will make a real impact in diabetes. What all three have in common, besides having nearly unlimited resources, strong brand name recognition and previous failed attempts in diabetes is...

Reality vs. Fantasy

This morning Abbott reported fourth quarter and full year results which for Libre came in as expected. For the full year diabetes care sales surpassed the $3 Billion level coming in at almost $3.3 Billion. With results like that, with a market that continues to grow, with system adoption increasing and new applications being found it’s easy to understand why everyone is going gaga over these rumors that Apple and...

Here we go yet again

It’s not surprising that once again rumors are circulating that Apple is adding glucose monitoring to the Apple Watch. According to a story published on the MacRumors website. “Apple is intending to bring blood glucose monitoring to the upcoming Apple Watch Series 7 using a non-invasive optical sensor.” Another report on the ETNews website states suggest that Samsung is also looking into the same technology for their upcoming Galaxy Watch 4. We hate...

Hotel California

Hotel California is not just a great Eagles song it’s also a story about our wacky world. As the song goes “ you can check out, but you never leave.” The latest guest is none other than Senseonics the makers of the Eversense implantable CGM. Now let’s be clear about a few things unlike so many other Dexcom and Abbott wannabes the product works and is being used by patients....

We also have a dream

Today as America celebrates the legacy and impact of Dr. King a man with a dream. The wacky world of diabetes also has a dream. No it’s not the dream of Dr. King but to the millions of us with diabetes it’s a reoccurring dream each time we check our sugars, administer insulin or take a pill. We dream of the day when we don’t have to do any of...

No sense plus nonsense does not equal common sense

For years we have been extolling the virtues of Tyler. Thanks to advanced insulin delivery technology, either a connected insulin pen or insulin pen cap cover, CGM and insulin dosing algorithms patients following multiple daily injection (MDI) therapy can achieve insulin pump like outcomes at a fraction of the cost of an insulin pump. As we have stated many times Tyler is the single largest threat to the insulin pump...

What happens after COVID?

Years from now after COVID is gone people will look back and see companies that built on the opportunity that Covid created and others that blew it. The reality is Covid for all the hardship it has and continues to create also created opportunities. Nowhere is this more evident than the explosion of virtual health companies. Prior to Covid telehealth was a technology used by a few with vast untapped...

Not the sharpest …..

This morning Dexcom released preliminary fourth quarter results along with guidance for 2021. At first we couldn’t figure out why then we remembered that today marks the beginning of the J P Morgan Healthcare Conference which like every other conference is now a virtual event. The results as per Dexcom tradition came in just fine with the 2021 guidance disappointing also a Dexcom tradition. Naturally shares have been selling off...

It’s about time

Yesterday Tidepool announced that finally at long last they have submitted their app to the FDA. Per a company issued press release “Tidepool, a 501(c)3 nonprofit, today announced completion of its FDA submission of Tidepool Loop, an automated insulin dosing app intended for the management of type 1 diabetes. The nonprofit was notified on December 22, 2020, that the submission had completed FDA’s administrative acceptance review and was proceeding to substantive review...